Observing the Efficacy of Combining Erlotinib with the Traditional Chinese Medi-cine Method of Yifei Fuzheng Jiandu in Treating Patients with Mid-Late Stage Lung Adenocarcinoma
Objective To explore the therapeutic efficacy of combining erlotinib with the Yifei Fuzheng Jiedu method of traditional Chinese medicine(TCM)in treating patients with mid-late stage lung adenocarcinoma.Methods 98 patients with mid-late stage lung adenocarcinoma,admitted to The People's Hospital of Kaizhou District,Chongqing,from September 2020 to September 2022,were selected as research subjects.They were divided into a control group and a study group,with 49 patients in each group according to the simple random number table method.The control group was treated with erlotinib,while the study group was treated with the Yifei Fuzheng Jiedu method in addition to erlotinib.Both groups were treated for 3 months.Tumor efficacy,TCM syndrome efficacy,the incidence of toxic side effects,TCM syn-drome scores,and levels of tumor markers[cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 125(CA1 25),carcinoembryonic antigen(CEA)]were observed and compared before and after treatment in both groups.Results After treatment,the tumor control rate of the study group(91.84％,45/49)was significantly higher than that of the control group(75.51％,37/49),with a statistically significant difference(P＜0.05).The overall effective rate of TCM syndrome effica-cy was higher in the study group(89.80％,44/49)compared to the control group(73.47％,36/49),with a statistically significant difference(P＜0.05).After treatment,the scores for primary symptoms(shortness of breath,chest tightness and pain,fatigue,blood in sputum,cough)and secondary symptoms(spontaneous sweating,night sweating,dry mouth with little fluid intake)were significantly lower than pre-treatment scores in both groups(P＜0.05).Moreover,the study group's symptom scores were significantly lower than those of the control group(P＜0.05).After treatment,serum levels of CY-FRA21-1,CA125,and CEA were significantly decreased in both groups(P＜0.05),with the study group showing signifi-cantly lower levels than the control group(P＜0.05).During the treatment period,the incidence of side effects such as thrombocytopenia,leukopenia,reduced hemoglobin,alopecia,elevated alanine aminotransferase,and peripheral nerve abnor-malities was lower in the study group than in the control group(P＜0.05).Conclusion Combining erlotinib with the Yifei Fuzheng Jiedu method of TCM method for the treatment of mid-late stage lung adenocarcinoma can effectively en-hance the therapeutic efficacy,reduce toxic side effects,significantly lower tumor marker levels,alleviate clinical symp-toms,improve the overall intervention effect,and reduce the incidence of toxic side effects.
ErlotinibYifei Fuzheng JianduLung AdenocarcinomaIncrease Efficiency and Reduce Toxicity
NETL
NSTL
万方数据
